0 ? 'text-green' : 'text-red') + '">'; htmlElements += (tickerData[i].Pricediff > 0 ? '+' : '') + ' ' + numberformat(tickerData[i].Pricediff) + '
Interactive reads from the businessline desk
FILE PHOTO: Zydus Sunshine Lifesciences has signed an agreement to establish a pharmaceutical manufacturing facility in Horana, Sri Lanka, with an investment of over $20 million.
Zydus Sunshine Lifesciences, a joint venture between Zydus Lifesciences Ltd and Sunshine Healthcare, has signed an agreement with the Board of Investment of Sri Lanka to set up a pharmaceutical manufacturing facility in the island nation, according to a regulatory filing on Thursday.
The project involves a phased investment of over USD 20 million.
The facility will be established on a site spanning nearly four acres in the Board of Investment (BOI) zone located in Horana, Sri Lanka.
Commercial operations at the unit are expected to start in 2028, subject to project timelines and relevant regulatory approvals, the company said.
"The investment supports Zydus' international presence and commitment to expanding access to quality medicines. Local manufacturing is expected to strengthen medicine supply chain resilience and support the availability of essential medicines in Sri Lanka," the company stated.
Sunshine Healthcare is part of Sunshine Holdings PLC. Both companies had previously announced the formation of the joint venture on June 26, 2026, and the agreement with the Board of Investment of Sri Lanka was signed on October 13, 2026.
Copyright© 2026, THG PUBLISHING PVT LTD. or its affiliated companies. All rights reserved.
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.
Terms & conditions | Institutional Subscriber
Loading comments…